Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in japan

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 591-595

  Mitsui, Tetsuo ^a,g   Mori, Tetsuya ^b   Fujita, Naoto ^c   Inada, Hiroko ^d   Horibe, Keizo ^e   Tsurusawa, Masahito ^f  

^a YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^f AICHI MEDICAL UNIVERSITY   (Japan)

^g NONE   (Japan)

Author keywords

Children; Lymphoblastic lymphoma; Recurrence; Refractory

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; THIOTEPA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JAPAN; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CHILD; DISEASE COURSE; INFANT; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; JAPAN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63649136332     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21941     Document Type: Article

References (16)

1. Reiter A, Schrappe M, Ludwig W-D, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: BFM Group report. Blood 2000;15:416-421.
2. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in Childhood. N Engl J Med 1996;334:1238-1248.
3. Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytrabin, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group study CCG-5912. J Clin Oncol 2001;19:2390-2396.
4. Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first line treatment: A population-based analysis of the Austrian Cooperative Study Group. Pediat Blood Cancer 2005;44:70-76.
5. Wollner N, Burchenal J, Lieberman P, et al. Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy. Cancer 1976;37:123-134.
6. Reiter A, Schrappe M, Yakisan E, et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2. An intermediate term analysis of the non-B-NHL therapy group. BFM Study Group. Klin Padiatr 1994;206:234-241.
7. Fields KK, Zorsky PE, Hiemenz JW, et al. Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity. J Clin Oncol 1994;12:544-552.
8. Burkhardt B, Reiter A, Lang P, et al. Relapse in pediatric patients with T-cell lymphoblastic lymphoma: Clinical characteristics and outcome in the BFM group. Pediat Blood Cancer 2006;46:842.
9. Sandlund I, Bowman I, Heslop H, et al. Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy 2002;4:253-258.
10. Dopfer R, Henze G, Bender-Gotze C, et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: Results of the German cooperative study. Blood 1991;78:2780-2784.
11. Borgmann A, Stackelberg Av, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003;101:3835-3839.
12. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group Study CCG-1941. J Clin Oncol 2006; 24:3150-3156.
13. Harrison G, Richard S, Lawson S, et al. Comparison ofallogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol 2000;11:999 -1006.
14. Peniket AJ, Elvira MRd, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but with a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transpl 2003;31:667-678.
15. Levine JE, Harris RE, Loberiza FR, Jr., et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003;101:2476-2482.
16. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007;21:2316-2323.